AU2010362412A1 - Treatment of cancer/inhibition of metastasis - Google Patents

Treatment of cancer/inhibition of metastasis Download PDF

Info

Publication number
AU2010362412A1
AU2010362412A1 AU2010362412A AU2010362412A AU2010362412A1 AU 2010362412 A1 AU2010362412 A1 AU 2010362412A1 AU 2010362412 A AU2010362412 A AU 2010362412A AU 2010362412 A AU2010362412 A AU 2010362412A AU 2010362412 A1 AU2010362412 A1 AU 2010362412A1
Authority
AU
Australia
Prior art keywords
cells
ranolazine
cancer
hypoxia
riluzole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010362412A
Other languages
English (en)
Inventor
Mustafa Bilgin Ali Djamgoz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2010362412A1 publication Critical patent/AU2010362412A1/en
Priority to AU2017202267A priority Critical patent/AU2017202267B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2010362412A 2010-10-13 2010-10-13 Treatment of cancer/inhibition of metastasis Abandoned AU2010362412A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017202267A AU2017202267B2 (en) 2010-10-13 2017-04-06 Treatment of cancer/inhibition of metastasis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2010/001908 WO2012049440A1 (en) 2010-10-13 2010-10-13 Treatment of cancer/inhibition of metastasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017202267A Division AU2017202267B2 (en) 2010-10-13 2017-04-06 Treatment of cancer/inhibition of metastasis

Publications (1)

Publication Number Publication Date
AU2010362412A1 true AU2010362412A1 (en) 2013-05-30

Family

ID=44022817

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2010362412A Abandoned AU2010362412A1 (en) 2010-10-13 2010-10-13 Treatment of cancer/inhibition of metastasis
AU2017202267A Active AU2017202267B2 (en) 2010-10-13 2017-04-06 Treatment of cancer/inhibition of metastasis

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017202267A Active AU2017202267B2 (en) 2010-10-13 2017-04-06 Treatment of cancer/inhibition of metastasis

Country Status (13)

Country Link
US (5) US20130203764A1 (enExample)
EP (4) EP2627321A1 (enExample)
JP (1) JP2013539778A (enExample)
KR (1) KR20140032346A (enExample)
CN (2) CN103370060A (enExample)
AU (2) AU2010362412A1 (enExample)
BR (1) BR112013009086A2 (enExample)
CA (1) CA2851694C (enExample)
DK (1) DK3132791T3 (enExample)
IL (1) IL225689A0 (enExample)
RU (1) RU2013121744A (enExample)
SG (1) SG189352A1 (enExample)
WO (1) WO2012049440A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013121744A (ru) 2010-10-13 2014-11-20 Мустафа Билгин Али ДЖАМГОЗ Лечение рака/ингибирование метастазирования
WO2013123403A1 (en) * 2012-02-15 2013-08-22 Sanford-Burnham Medical Research Institute Theranostics platform and methods of use
WO2017091574A1 (en) * 2015-11-25 2017-06-01 Health Research, Inc. Riluzole and riluzole drug combinations for the treatment of prostate cancer
JP6465306B2 (ja) * 2016-02-04 2019-02-06 セレックス・オンコロジー・リミテッド 癌の治療／転移の阻害
IL292302B2 (en) * 2016-05-20 2023-10-01 Biohaven Pharm Holding Co Ltd Use of glutamate modulating factors in cancer immunotherapy
CN110662545A (zh) * 2017-02-10 2020-01-07 赛立斯肿瘤学创新有限公司 癌症治疗和转移抑制
US20200123544A1 (en) * 2018-10-22 2020-04-23 Celex Oncology Innovations Limited Gene therapy targeting the neonatal form of nav1.5 for treating cancer
WO2021078987A1 (en) 2019-10-24 2021-04-29 Celex Oncology Innovations Limited Combination treatments for cancer
US12624101B2 (en) 2020-01-21 2026-05-12 Celex Oncology Innovations Limited Monoclonal antibodies against neonatal Nav1.5
US20230139204A1 (en) 2020-03-09 2023-05-04 Celex Oncology Innovations Limited Measuring electric activity of cells for the evaluation of metastatic potential of cancer cells
WO2022005228A1 (ko) * 2020-07-01 2022-01-06 국립암센터 3-케토아실 coa 타이올레이스 억제제 및 카르니틴 아실카르니틴 운반자 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물
WO2025078664A1 (en) 2023-10-12 2025-04-17 Celex Oncology Innovations Limited Treatment of metastatic or invasive brain cancer
WO2025252860A1 (en) 2024-06-04 2025-12-11 Celex Oncology Innovations Limited Ranolazine enantiomer for use in cancer treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1659136A (zh) * 2002-04-18 2005-08-24 弗吉尼亚大学专利基金会 新的钠通道阻滞剂
CA2513399A1 (en) * 2003-01-10 2004-07-29 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
US8835473B2 (en) * 2004-04-16 2014-09-16 Rutgers, The State University Of New Jersey Methods and compositions for treating cancer
US9018222B2 (en) 2006-03-27 2015-04-28 Wex Medical Limited Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
US8394377B2 (en) * 2008-02-21 2013-03-12 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
US20090247535A1 (en) * 2008-03-26 2009-10-01 Duke University Use of ranolazine for non-cardiovascular disorders
US20110251144A1 (en) * 2008-09-16 2011-10-13 Massachusetts Institute Of Technology Molecular modulators of the wnt/beta-catenin pathway
RU2013121744A (ru) 2010-10-13 2014-11-20 Мустафа Билгин Али ДЖАМГОЗ Лечение рака/ингибирование метастазирования

Also Published As

Publication number Publication date
US20230202994A1 (en) 2023-06-29
US11634398B2 (en) 2023-04-25
BR112013009086A2 (pt) 2016-07-26
EP4640281A2 (en) 2025-10-29
EP3132791B1 (en) 2019-11-27
WO2012049440A1 (en) 2012-04-19
EP4640281A3 (en) 2026-01-07
AU2017202267B2 (en) 2019-01-24
US20160096812A1 (en) 2016-04-07
DK3132791T3 (da) 2020-03-09
RU2013121744A (ru) 2014-11-20
KR20140032346A (ko) 2014-03-14
IL225689A0 (en) 2013-06-27
CN112755029A (zh) 2021-05-07
US20130203764A1 (en) 2013-08-08
CA2851694C (en) 2019-02-26
EP3653206A1 (en) 2020-05-20
US12534444B2 (en) 2026-01-27
CA2851694A1 (en) 2012-04-19
US20200017457A1 (en) 2020-01-16
EP2627321A1 (en) 2013-08-21
EP3132791A1 (en) 2017-02-22
SG189352A1 (en) 2013-05-31
JP2013539778A (ja) 2013-10-28
US20180346431A1 (en) 2018-12-06
AU2017202267A1 (en) 2017-04-27
CN103370060A (zh) 2013-10-23

Similar Documents

Publication Publication Date Title
US12534444B2 (en) Treatment of cancer/inhibition of metastasis
Chopra et al. Expression and function of bradykinin B1 and B2 receptors in normal and inflamed rat urinary bladder urothelium
Tsuneki et al. Antiangiogenic activity of β-eudesmol in vitro and in vivo
US20220125800A1 (en) Treatment of cancer and inhibition of metastasis
WO2012049439A1 (en) Treatment of cancer/inhibition of metastasis
DE60326871D1 (de) Verfahren zur dosierung von ngf zur in vitro diagnose von brustkrebs und therapeutische verwendung
GB2484513A (en) Treatment of cancer/inhibition of metasesis using ranolazine or riluzole
JP2019001826A (ja) 癌の治療／転移の阻害
JP2022179708A (ja) 癌の治療／転移の阻害
JP6465306B2 (ja) 癌の治療／転移の阻害
Lee et al. Anti-metastatic and anti-angiogenic activities of a new matrix metalloproteinase inhibitor, TN-6b
CN114177169B (zh) 一种使用硫化氢缓释供体adt-oh抑制黑色素瘤转移的方法及其应用
Wohlrab et al. The influence of lidocaine and verapamil on the proliferation, CD44 expression and apoptosis behavior of human chondrocytes
Cui et al. Ketamine inhibits lung fluid clearance through reducing alveolar sodium transport
Broso Alpha-1-Adrenergic receptors as new targets in Neuroblastoma
Karthikeyan Characterization of Spontaneous Motor Recovery and Changes in Plasticity-Limiting Perineuronal Nets Following Cortical and Subcortical Stroke
Wong TIMING AND VOLUME OF TOPICAL TRANEXAMIC ACID ADMINISTRATION FOR POSTOPERATIVE BLOOD LOSS IN TOTAL KNEE ARTHROPLASTY
Aaronson et al. Role of protein kinase C and reactive oxygen species in hydro-gen sulfide mediated contraction of rat small pulmonary arteries
Yi et al. Antiꠂangiogenic Activity of KRꠂ31482, a New Benzopyran Derivative
Hsieh et al. 281: Instillation of Liposomes is Superior to DMSO or Pentosan Polysulfate in Reducing Bladder Hyperactivity

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted